NexImmune, Inc. (NEXI)

Develops therapies for cancer and autoimmune diseases, focusing on artificial antigen-presenting cells and immunotherapies.

NEXI Stock Quote

Company Report

NexImmune, Inc. is a dynamic clinical-stage biotechnology company focused on pioneering therapies with potential curative effects for patients battling cancer and severe immune-mediated diseases. Central to its innovative approach is the development of T cell immunotherapies leveraging its proprietary Artificial Immune Modulation nanoparticle technology platform.

At the forefront of NexImmune's pipeline are several promising product candidates. NEXI-001, an allogeneic cell therapy, is currently advancing through Phase I/II clinical trials aimed at treating patients with acute myeloid leukemia. Similarly, NEXI-002, an autologous cell therapy, is in Phase I/II trials targeting individuals with relapsed and/or refractory multiple myeloma. Additionally, the company is developing NEXI-003, a candidate designed to combat HPV-associated malignancies, currently in the preclinical stage of development.

Founded in 2011 and headquartered in Gaithersburg, Maryland, NexImmune continues to push boundaries in biotechnology innovation. With a steadfast commitment to advancing transformative therapies, the company is poised to make significant strides in improving outcomes for patients confronting challenging and life-threatening conditions globally.

NEXI EPS Chart

NEXI Revenue Chart

Stock Research

CODI MBUU MUSA GHC IBM CTHR PDM

NEXI Chart

View interactive chart for NEXI

NEXI Profile

NEXI News

Analyst Ratings